Dr. Stephen LaMond - 15 Sep 2023 Form 4/A - Amendment Insider Report for Peak Bio, Inc.

Role: Interim Chief Executive Officer, Director
Signature: /s/ Dr. Stephen LaMond
Issuer symbol: N/A
Transactions as of: 15 Sep 2023
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 28 Sep 2023, 16:05:04 UTC
Date Of Original Report: 19 Sep 2023
Previous filing: 03 Nov 2022
Next filing: 28 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PKBO	Common Stock	Purchase		+11,750			11,750	15 Sep 2023	Direct	F1
transaction	PKBO	Common Stock	Purchase		+2,500	+21%		14,250	18 Sep 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Dr. LaMond previously reported purchases of 26,000 shares of the Company's Common Stock on September 15, 2023 in error. Instead, on September 15, 2023, Dr. Stephen LaMond purchased a total of 11,750 shares of the Company's Common Stock at prices ranging from $0.27 per share to $0.43 per share.
F2	On September 18, 2023, Dr. Stephen LaMond purchased a total of 2,500 shares of the Company's Common Stock at prices ranging from $0.23 per share to $0.29 per share.

Remarks:

Interim Chief Executive Officer